Trellus Health PLC Posting of Annual Report & Accounts (7651M)
25 May 2022 - 9:00PM
UK Regulatory
TIDMTRLS
RNS Number : 7651M
Trellus Health PLC
25 May 2022
Trellus Health plc
("Trellus Health" or the "Company")
Posting of Annual Report & Accounts
and
Notice of Annual General Meeting
LONDON, UK. AND NEW YORK, U.S. (25 May 2022). Trellus Health plc
(AIM: TRLS), which is commercialising a scientifically validated,
resilience-based, connected health solution for chronic condition
management, confirms that the Annual Report and Accounts for the
year ended 31 December 2021 ("2021 Annual Report") and the Notice
of the 2022 Annual General Meeting ("AGM") have now been published
on the Company's website here .
The 2021 Annual Report, the Notice of AGM and details for voting
by proxy will be posted to shareholders today, on 25 May 2022.
Beneficial shareholders who received Trellus shares from the
distribution in specie by EKF Diagnostics Holdings plc will receive
details for voting by proxy in the post.
The AGM is to be held at 2:00pm on 27 June 2022 at the Company's
registered offices, at Avon House, 19 Stanwell Road, Penarth,
Cardiff, CF64 2EZ and will consider the Resolutions set out in the
Notice of AGM.
The Company is providing a facility for shareholders to listen
in to the AGM either online or telephonically (in a non-voting
capacity) and there will be an opportunity for shareholders to ask
questions. In order to facilitate the process, the Directors would
request that shareholders register for the meeting and submit
questions in advance, before 2:00pm on 24 June 2022. To register
for dial-in details and to submit any questions please contact
Walbrook PR via email at trellus@walbrookpr.com or call +44 (0)20
7933 8780.
Proxy voting
Shareholders will not receive a hard copy form of proxy for the
2022 AGM in the post. Instead, Shareholders will be able to vote
electronically using the link www.signalshares.com . Proxy votes
must be received no later than 2:00pm on 23 June 2022.
Shareholders may request a hard copy form of proxy directly from
the Registrars, Link Group, on Tel: 0371 664 0300. Calls are
charged at the standard geographic rate and will vary by provider.
Calls outside the United Kingdom will be charged at the applicable
international rate. Lines are open between 09:00 - 17:30, Monday to
Friday excluding public holidays in England and Wales.
For further information please contact:
Trellus Health plc www.trellushealth.com
M onique Fayad , CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Tel: 020 7496 3000
Adviser & Broker)
Aubrey Powell / Jen Boorer
Walbrook PR Limited Tel: 020 7933 8780 or trellus@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502 558 258
About Trellus Health plc (www.trellushealth.com)
Trellus Health (LSE: TRLS) is the first digital health company
focused on the intersection of chronic physical conditions and
mental health. Trellus Health integrates its proprietary
resilience-based methodology with the technology, tools and team to
deliver a whole-person technology-enhanced experience that results
in relieving disease burden and promoting individual health
behaviors that enable thriving in the face of a chronic condition.
Through its TrellusElevate(TM) connected care platform and
companion App, the company addresses both clinical and behavioral
health together, in context, to improve outcomes and reduce
healthcare costs for patients, employers, and the healthcare
system.
The Company is initially focused on Inflammatory bowel disease
("IBD"), which includes the chronic incurable conditions of Crohn's
Disease and ulcerative colitis, but considers its approach to have
potential utility and demand across many chronic conditions,
including Irritable Bowel Syndrome ("IBS").
The TrellusElevate(TM) platform is the Company's proprietary
connected health platform that incorporates the GRITT(TM)
methodology and learnings on resilience from clinical research and
practice conducted at the Mount Sinai IBD Center for more than five
years. This proprietary, resilience-driven methodology has been
scientifically validated to demonstrate meaningful improvements in
patient outcomes, 71% reduction in Emergency Department (A&E)
visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for
significant cost savings for healthcare payers. IBD patients
treated using the methodology also experienced a 49% reduction in
required opioid use and a 73% reduction in corticosteroid use 12
months following program completion (source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
).
The Company was founded by Mount Sinai faculty members Dr. Marla
C. Dubinsky, MD and Dr. Laurie Keefer, PhD, both with decades of
combined experience in IBD and psychogastroenterology,
respectively. Trellus Health's patent-pending GRITT(TM) resilience
assessment and personalized treatment methodology was developed and
validated at the Mount Sinai Health System to build resilience and
wellness for improved outcomes at lower cost.
Shares in Trellus Health were admitted to trading on AIM in May
2021, under the ticker TRLS. For more information on Trellus
Health, visit: www.trellushealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOASEMSUIEESEFI
(END) Dow Jones Newswires
May 25, 2022 07:00 ET (11:00 GMT)
Trellus Health (LSE:TRLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trellus Health (LSE:TRLS)
Historical Stock Chart
From Jul 2023 to Jul 2024